MARC Record from marc_columbia

LEADER: 02171cam a2200385 a 4500
001 8388738
005 20221201061935.0
008 100721t20112011paua b 001 0 eng
010 $a 2010031113
016 7 $a101536380$2DNLM
020 $a9780781796934
020 $a0781796938
029 1 $aNLM$b101536380
035 $a(OCoLC)ocn650953409
035 $a(OCoLC)650953409
035 $a(NNC)8388738
035 $a8388738
040 $aDNLM/DLC$cDLC$dYDX$dNLM$dYDXCP
042 $apcc
050 00 $aRC271.R26$bT37 2011
060 10 $aQZ 269
082 00 $a616.99/40642$222
245 00 $aTargeted radionuclide therapy /$ceditor, Tod W. Speer.
260 $aPhiladelphia :$bWolters Kluwer Health/Lippincott Williams & Wilkins,$c[2011], ©2011.
300 $axvii, 537 pages :$billustrations (some color) ;$c29 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
520 $a"Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion"--Provided by publisher.
650 0 $aCancer$xRadioimmunotherapy.$0http://id.loc.gov/authorities/subjects/sh89007034
650 12 $aNeoplasms$xradiotherapy.$0https://id.nlm.nih.gov/mesh/D009369Q000532
650 22 $aRadioisotopes$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D011868Q000627
650 22 $aRadiotherapy$xmethods.$0https://id.nlm.nih.gov/mesh/D011878Q000379
700 1 $aSpeer, Tod W.$0http://id.loc.gov/authorities/names/n2010182993
852 00 $boff,hsl$hRC271.R26$iT37 2011 Q